Dyne Therapeutics, Inc. (DYN)
Stock Price:
$19.61 USD
0.05 (0.26%)
Updated November 25, 4:00 PM EST - Market closed
Key Info
| Market Cap |
891.18M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-54.08M |
| Shares Out |
45.45M |
| EPS (ttm) |
-1.19 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 25 |
| Last Price |
$19.61 |
| Previous Close |
$19.56 |
| Change ($) |
0.05 |
| Change (%) |
0.26% |
| Day's Open |
19.55 |
| Day's Range |
19.19 - 20.12 |
| Day's Volume |
106,045 |
| 52-Week Range |
15.60 - 27.11 |
More Stats
| Market Cap |
891.18M |
| Enterprise Value |
521.51M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
45.45M |
| Float |
16.96M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.19 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.39 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-54.08M |
| Free Cash Flow |
n/a |
| Net Cash |
369.67M |
| Net Cash / Share |
8.13 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$34.25*
(74.66% upside)
Low
27.0
Current: $19.61
High
47.0
Target: 34.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -13.83 | -4.80 |
| Net Income | -14.86 | -4.81 |
| Shares Outstanding | 2.44 | 0.47 |
| Earnings Per Share | -6.08 | -10.15 |
| Operating Cash Flow | -11.83 | -4.16 |
| Capital Expenditures | -1.65 | -0.13 |
| Free Cash Flow | -13.48 | -4.30 |
| Cash & Equivalents | 14.63 | 8.12 |
| Net Cash / Debt | 14.63 | 8.12 |
| Assets | 16.44 | 8.27 |
| Liabilities | 2.40 | 4.09 |
| Book Value | 14.04 | -4.88 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Dyne Therapeutics, Inc. |
| Country |
United States |
| Employees |
36 |
| CEO |
Joshua T. Brumm |
Stock Information
| Ticker Symbol |
DYN |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: DYN |
| IPO Date |
September 17, 2020 |
Description
Dyne Therapeutics, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.